HighVista Initiates Position in Cidara with 70,904 Shares Worth $6.79 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 02 2026
0mins
Should l Buy MRK?
Source: NASDAQ.COM
- New Investment Position: HighVista Strategies initiated a position in Cidara Therapeutics by acquiring 70,904 shares valued at $6.79 million during Q3 2025, representing 1.66% of its 13F reportable assets, indicating a strategic interest in the biotech sector.
- Outstanding Market Performance: As of November 13, 2025, Cidara's shares were priced at $105.99, reflecting a remarkable 662.52% increase over the past year, with a one-year alpha of 675.44 percentage points, showcasing strong market confidence in its future prospects.
- Acquisition News: Cidara recently announced its acquisition by Merck at a price of $221.50 per share, which is expected to keep its stock price elevated in the short term, reflecting market anticipation for its promising influenza prevention drug candidate, CD388.
- Strategic Implications: HighVista's investment comes at a pivotal moment, as Cidara's shareholders stand to benefit from potential drug sales following the Merck acquisition, while HighVista's new stake may yield significant returns in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 116.370
Low
95.00
Averages
119.53
High
139.00
Current: 116.370
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MERCK & CO INC ANTICIPATES $5.8 BILLION CHARGE OF APPROXIMATELY $2.35 PER SHARE IN Q2 AND FY2026, WITH DEAL CLOSURE EXPECTED IN Q2 2026
Merck & Co. Deal Closure: Merck & Co. is expected to finalize a significant deal in the second quarter of 2026.
Financial Implications: The deal is projected to incur a charge of approximately $2.35 per share in the second quarter and will impact the financial results for the fiscal year 2026.
See More
MERCK & CO INC - TRANSACTION VALUED AT APPROXIMATELY $5.7 BILLION NET OF CASH, REFLECTING A 31% PREMIUM OVER 60-DAY VWAP AS OF MARCH 24, 2026
- Deal Overview: Merck & Co has announced a deal valued at approximately $5.7 billion.
- Premium Details: The deal includes a 31% premium based on the 60-day volume-weighted average price (VWAP) as of March 24, 2026.
See More
Merck & Co Inc Acquires Terns Pharmaceuticals at $53.00 Per Share, Valuing Equity at $6.7 Billion
- Acquisition Announcement: Merck & Co. has announced its intention to acquire Terns Pharmaceuticals for $53.00 per share.
- Valuation Details: The total equity value of the acquisition is estimated at $6.7 billion.
See More
Merck to Purchase Terns Pharmaceuticals, Enhancing Hematology Pipeline with TERN-701, a New Treatment for Chronic Myeloid Leukemia (CML)
Merck's Acquisition: Merck has acquired Terns Pharmaceuticals, Inc. to enhance its hematology pipeline.
Focus on Chronic Myeloid Leukemia: The acquisition includes Terns' novel candidate, TERN-701, which is aimed at treating chronic myeloid leukemia (CML).
See More
MERCK CLOSES IN ON $6BN BIOTECH ACQUISITION TO ENHANCE CANCER DRUG PORTFOLIO - FT
- Merck's Acquisition: Merck is set to acquire a biotechnology company for approximately $6 billion to enhance its cancer drug pipeline.
- Strategic Focus: This deal reflects Merck's commitment to expanding its portfolio in oncology and strengthening its position in the competitive cancer treatment market.
See More
Merck's $6.7 Billion Tern Acquisition Faces Investor Scrutiny
- Acquisition Premium Concerns: Merck's acquisition of Tern Pharmaceuticals for $6.7 billion at $53 per share represents only a 6% premium, raising investor concerns about whether this premium is adequate for a high-probability asset, suggesting a lack of confidence from both Merck and Tern in the drug's potential.
- Investor Reactions: RBC analyst Trung Huynh noted that while some investors defend the $6.7 billion price as reasonable, there is a mixed market response, with expectations of competing bids or shareholder rejection of the deal.
- Market Expectations: Tern's stock had already surged 25% prior to the deal announcement, which somewhat mitigates the perception of a weak premium, indicating that the market recognizes the asset's potential value.
- Future Developments: RBC anticipates the release of a 14D-9 document early next month, which will provide more details about the transaction, and investors are adopting a wait-and-see approach, looking for potential competitive bids in the future.
See More
MERCK & CO INC ANTICIPATES $5.8 BILLION CHARGE OF APPROXIMATELY $2.35 PER SHARE IN Q2 AND FY2026, WITH DEAL CLOSURE EXPECTED IN Q2 2026
Merck & Co. Deal Closure: Merck & Co. is expected to finalize a significant deal in the second quarter of 2026.
Financial Implications: The deal is projected to incur a charge of approximately $2.35 per share in the second quarter and will impact the financial results for the fiscal year 2026.
See More
MERCK & CO INC - TRANSACTION VALUED AT APPROXIMATELY $5.7 BILLION NET OF CASH, REFLECTING A 31% PREMIUM OVER 60-DAY VWAP AS OF MARCH 24, 2026
- Deal Overview: Merck & Co has announced a deal valued at approximately $5.7 billion.
- Premium Details: The deal includes a 31% premium based on the 60-day volume-weighted average price (VWAP) as of March 24, 2026.
See More
Merck & Co Inc Acquires Terns Pharmaceuticals at $53.00 Per Share, Valuing Equity at $6.7 Billion
- Acquisition Announcement: Merck & Co. has announced its intention to acquire Terns Pharmaceuticals for $53.00 per share.
- Valuation Details: The total equity value of the acquisition is estimated at $6.7 billion.
See More
Merck to Purchase Terns Pharmaceuticals, Enhancing Hematology Pipeline with TERN-701, a New Treatment for Chronic Myeloid Leukemia (CML)
Merck's Acquisition: Merck has acquired Terns Pharmaceuticals, Inc. to enhance its hematology pipeline.
Focus on Chronic Myeloid Leukemia: The acquisition includes Terns' novel candidate, TERN-701, which is aimed at treating chronic myeloid leukemia (CML).
See More
MERCK CLOSES IN ON $6BN BIOTECH ACQUISITION TO ENHANCE CANCER DRUG PORTFOLIO - FT
- Merck's Acquisition: Merck is set to acquire a biotechnology company for approximately $6 billion to enhance its cancer drug pipeline.
- Strategic Focus: This deal reflects Merck's commitment to expanding its portfolio in oncology and strengthening its position in the competitive cancer treatment market.
See More
Merck's $6.7 Billion Tern Acquisition Faces Investor Scrutiny
- Acquisition Premium Concerns: Merck's acquisition of Tern Pharmaceuticals for $6.7 billion at $53 per share represents only a 6% premium, raising investor concerns about whether this premium is adequate for a high-probability asset, suggesting a lack of confidence from both Merck and Tern in the drug's potential.
- Investor Reactions: RBC analyst Trung Huynh noted that while some investors defend the $6.7 billion price as reasonable, there is a mixed market response, with expectations of competing bids or shareholder rejection of the deal.
- Market Expectations: Tern's stock had already surged 25% prior to the deal announcement, which somewhat mitigates the perception of a weak premium, indicating that the market recognizes the asset's potential value.
- Future Developments: RBC anticipates the release of a 14D-9 document early next month, which will provide more details about the transaction, and investors are adopting a wait-and-see approach, looking for potential competitive bids in the future.
See More
